| Old Articles: <Older 8541-8550 Newer> |
|---|
 |
Chemistry World
March 5, 2013
Andrew Turley |
Alcohol dependence pill approved in EU Danish drug maker Lundbeck has been granted European marketing approval for Selincro (nalmefene) tablets to treat alcohol dependence.   |
Pharmaceutical Executive
February 1, 2013
Ben Comer |
Drugged Driving NHTSA is working on a structured, standardized protocol for assessing the driving-impairment risks of drugs. |
Chemistry World
March 4, 2013
Andy Extance |
UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries. |
IEEE Spectrum
March 2013
Eliza Strickland |
The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine |
IEEE Spectrum
March 2013
Susan Hassler |
Genome to Go It's already possible to have your own genome sequenced. But personalized medicine based on sequencing still has a way to go |
Chemistry World
February 27, 2013
Andrew Turley |
Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma. |
Chemistry World
February 27, 2013
Anthony King |
PharmaSea to scour ocean depths for new drugs A new project will soon see scientists trawling the ocean bottoms for new bioactive compounds. Scientists on the PharmaSea mission will haul samples of mud and sediment from the deep sea, isolating marine organisms in the hunt for novel drug candidates. |
Chemistry World
February 21, 2013
Andrew Turley |
$595m octreotide deal grabs Roche Swiss drugmaker Roche has struck a $595 million deal with US firm Chiasma for Octreolin (octreotide) tablets for treating acromegaly, a rare condition that causes excessive growth |
Chemistry World
February 19, 2013
Andrew Turley |
Merck resolves Vytorin case for $688m Merck & Co has agreed to pay $688 million to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin). |
Chemistry World
February 14, 2013
Andrew Turley |
BMS sells OTC drugs for $482m UK consumer goods giant Reckitt Benckiser has struck a $482 million deal to buy from Bristol-Myers Squibb rights to a range of over-the-counter drugs in parts of Latin America, including Brazil and Mexico. |
| <Older 8541-8550 Newer> Return to current articles. |
